Co-diagnostics Share Price (NASDAQ: CODX)

$0.33

▲

-0.01

(-2.94%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Co-diagnostics Stock chart to analyse performance

Co-diagnostics stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$0.33
Today's High:$0.34
$0.33
0.33%
Downside
Day's Volatility :2.69%
Upside
2.37%
52 Weeks Low:$0.23
52 Weeks High:$1.58
$0.33
31.06%
Downside
52 Weeks Volatility :85.6%
Upside
79.11%

Co-diagnostics Stock Returns

Period	Co-diagnostics Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	25.92%	3.6%	0.0%
6 Months	-31.21%	-7.7%	0.0%
1 Year	-74.89%	-12.6%	0.0%
3 Years	-89.69%	9.5%	-4.7%

Co-diagnostics Inc Key Stats

Check Co-diagnostics key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$0.34
Open	$0.336
Today's High	$0.338
Today's Low	$0.3289
Market Capitalization	$12.9M
Today's Volume	$264.1K
52 Week High	$1.58
52 Week Low	$0.2275
Revenue TTM	$1.0M
EBITDA	$-37.5M
Earnings Per Share (EPS)	$-1.15
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.31%
Return On Equity TTM	-63.4%

Stock Returns calculator for Co-diagnostics Stock including INR - Dollar returns

The Co-diagnostics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Co-diagnostics investment value today

Current value as on today

₹30,475

Returns

₹69,525

(-69.53%)

Returns from Co-diagnostics Stock

₹74,809 (-74.81%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Co-diagnostics Stock

-6%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Co-diagnostics Stock from India on INDmoney has decreased by -6% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Co-diagnostics Inc

Name
Holdings %
Name
Holdings %
Vanguard Group Inc
4.79%
Private Asset Group LLC
3.27%
Renaissance Technologies Corp
1.52%
BlackRock Inc
1.39%
Geode Capital Management, LLC
0.95%
Susquehanna International Group, LLP
0.59%

Analyst Recommendation on Co-diagnostics Stock

Rating

Trend

Sell

0%Buy

50%Hold

50%Sell

Based on 6 Wall street analysts offering stock ratings for Co-diagnostics(by analysts ranked 0 to 5 stars)

Co-diagnostics Share Price Target

What analysts predicted

Upside of 2930.3%

Target:

$10.00

Current:

$0.33

Co-diagnostics share price target is $10.00, a slight Upside of 2930.3% compared to current price of $0.33 as per analysts' prediction.

Co-diagnostics Stock Insights

Price Movement
In the last 1 month, CODX stock has moved up by 28.2%
Increasing Revenue
Revenue is up for the last 2 quarters, 50.27K → 162.91K (in $), with an average increase of 69.1% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -7.53M → -7.73M (in $), with an average decrease of 2.6% per quarter
CODX vs BSX (1 yr)
In the last 1 year, Boston Scientific Corp. has given 29.0% return, outperforming this stock by 105.3%
CODX vs BSX (3 yr)
In the last 3 years, Boston Scientific Corp. has given 163.5% return, outperforming this stock by 254.2%
Price to Sales
ForCODX every $1 of sales, investors are willing to pay $10.3, whereas for Boston Scientific Corp., the investors are paying $8.4 for every $1 of sales.

Co-diagnostics Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$215.0K	↑ 438.63%
Net Income	$-6.1M	↓ 3.23%
Net Profit Margin	-2.8K%	↑ 12891.09%

	FY20	Y/Y Change
Revenue	$74.6M	↑ 34579.9%
Net Income	$42.5M	↓ 799.91%
Net Profit Margin	56.98%	↑ 2880.16%

	FY21	Y/Y Change
Revenue	$97.9M	↑ 31.3%
Net Income	$36.7M	↓ 13.7%
Net Profit Margin	37.45%	↓ 19.53%

	FY22	Y/Y Change
Revenue	$34.2M	↓ 65.04%
Net Income	$-14.2M	↓ 138.84%
Net Profit Margin	-41.61%	↓ 79.06%

	FY23	Y/Y Change
Revenue	$6.8M	↓ 80.09%
Net Income	$-35.3M	↑ 148.15%
Net Profit Margin	-518.68%	↓ 477.07%

	FY24	Y/Y Change
Revenue	$3.9M	↓ 42.53%
Net Income	$-37.6M	↑ 6.53%
Net Profit Margin	-961.37%	↓ 442.69%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$252.7K	↓ 92.89%
Net Income	$-9.3M	↓ 36.55%
Net Profit Margin	-3.7K%	↓ 3271.54%

	Q2 FY24	Q/Q Change
Revenue	$161.1K	↓ 36.26%
Net Income	$-7.6M	↓ 18.39%
Net Profit Margin	-4.7K%	↓ 1032.72%

	Q3 FY24	Q/Q Change
Revenue	$641.1K	↑ 297.97%
Net Income	$-9.7M	↑ 27.6%
Net Profit Margin	-1.5K%	↑ 3204.71%

	Q4 FY24	Q/Q Change
Revenue	$149.3K	↓ 76.71%
Net Income	$-11.0M	↑ 13.77%
Net Profit Margin	-7.4K%	↓ 5875.0%

	Q1 FY25	Q/Q Change
Revenue	$50.3K	↓ 66.33%
Net Income	$-7.5M	↓ 31.71%
Net Profit Margin	-15.0K%	↓ 7596.16%

	Q2 FY25	Q/Q Change
Revenue	$162.9K	↑ 224.02%
Net Income	$-7.7M	↑ 2.61%
Net Profit Margin	-4.7K%	↑ 10238.51%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$102.5K	↑ 235.99%

	FY20	Y/Y Change
Profit	$58.0M	↑ 56424.01%

	FY21	Y/Y Change
Profit	$86.3M	↑ 48.91%

	FY22	Y/Y Change
Profit	$28.7M	↓ 66.71%

	FY23	Y/Y Change
Profit	$2.6M	↓ 90.86%

	FY24	Y/Y Change
Profit	$2.9M	↑ 11.0%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$-312.3K	↓ 213.8%

	Q2 FY24	Q/Q Change
Profit	$-389.4K	↑ 24.67%

	Q3 FY24	Q/Q Change
Profit	$343.7K	↓ 188.28%

	Q4 FY24	Q/Q Change
Profit	$-105.7K	↓ 130.76%

	Q1 FY25	Q/Q Change
Profit	$28.7K	↓ 127.13%

	Q2 FY25	Q/Q Change
Profit	$130.8K	↑ 355.97%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-5.5M	↑ 35.42%
Investing Cash Flow	$-435.2K	↑ 14.44%
Financing Cash Flow	$5.9M	↑ 214.65%

	FY20	Y/Y Change
Operating Cash Flow	$28.2M	↓ 609.77%
Investing Cash Flow	$-5.8M	↑ 1238.17%
Financing Cash Flow	$19.7M	↑ 234.44%

	FY21	Y/Y Change
Operating Cash Flow	$41.1M	↑ 45.86%
Investing Cash Flow	$4.1M	↓ 170.37%
Financing Cash Flow	$450.4K	↓ 97.72%

	FY22	Y/Y Change
Operating Cash Flow	$6.6M	↓ 84.01%
Investing Cash Flow	$-58.2M	↓ 1519.19%
Financing Cash Flow	$-14.0M	↓ 3215.91%

	FY23	Y/Y Change
Operating Cash Flow	$-22.1M	↓ 436.17%
Investing Cash Flow	$15.4M	↓ 126.46%
Financing Cash Flow	$-1.4M	↓ 90.28%

	FY24	Y/Y Change
Operating Cash Flow	$-29.2M	↑ 32.03%
Investing Cash Flow	$17.1M	↑ 10.93%
Financing Cash Flow	$103.9K	↓ 107.62%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-8.5M	↑ 77.67%
Investing Cash Flow	$16.7M	↑ 73.4%
Financing Cash Flow	$0.0	↓ 100.0%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-5.2M	↓ 38.7%
Investing Cash Flow	$-4.0M	↓ 124.21%
Financing Cash Flow	$0.0	-

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-7.2M	↑ 38.92%
Investing Cash Flow	$4.2M	↓ 203.27%
Financing Cash Flow	$0.0	-

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-8.2M	↑ 13.85%
Investing Cash Flow	$266.0K	↓ 93.62%
Financing Cash Flow	$103.9K	-

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-8.7M	↑ 6.25%
Investing Cash Flow	$7.4M	↑ 2665.71%
Financing Cash Flow	$354.7K	↑ 241.38%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-8.3M	↓ 5.23%
Investing Cash Flow	$17.1M	↑ 132.04%
Financing Cash Flow	$429.0K	↑ 20.93%

Co-diagnostics Technicals Summary

Sell

Neutral

Buy

Co-diagnostics is currently in a neutral trading position according to technical analysis indicators.

Co-diagnostics Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Co-diagnostics Inc	27.18%	-31.21%	-74.89%	-89.69%	-96.88%
Medtronic Plc	3.87%	-1.59%	4.32%	4.82%	-13.69%
Edwards Lifesciences Corp.	2.55%	13.95%	18.33%	-9.73%	-5.31%
Boston Scientific Corp.	0.09%	0.6%	30.02%	157.38%	154.4%
Stryker Corporation	3.63%	-0.85%	8.87%	89.43%	97.71%
Abbott Laboratories	5.15%	-5.37%	15.72%	26.56%	24.53%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Co-diagnostics Inc	4.96	NA	0.0	-0.67	-0.63	-0.38	NA	1.14
Medtronic Plc	25.4	25.4	2.14	5.46	0.1	0.05	0.03	37.36
Edwards Lifesciences Corp.	34.03	34.03	4.85	2.5	0.16	0.08	NA	17.94
Boston Scientific Corp.	62.95	62.95	1.84	2.98	0.12	0.05	NA	15.14
Stryker Corporation	51.54	51.54	2.24	13.49	0.14	0.08	0.01	55.43
Abbott Laboratories	16.64	16.64	4.17	5.14	0.31	0.07	0.02	29.05

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Co-diagnostics Inc	Sell	$12.9M	-96.88%	4.96	0.0%
Medtronic Plc	Buy	$118.0B	-13.69%	25.4	13.63%
Edwards Lifesciences Corp.	Buy	$47.8B	-5.31%	34.03	72.96%
Boston Scientific Corp.	Buy	$156.7B	154.4%	62.95	13.55%
Stryker Corporation	Buy	$149.0B	97.71%	51.54	12.25%
Abbott Laboratories	Buy	$230.9B	24.53%	16.64	32.43%

About Co-diagnostics Inc

Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.

Organization	Co-diagnostics
Employees	132
CEO	Mr. Dwight H. Egan
Industry	Health Technology

Key Management of Co-diagnostics Inc

Name	Title
Mr. Dwight H. Egan	Chairman & CEO
Mr. Richard David Abbott	President
Mr. David Nielsen	Chief Operating Officer
Mr. Dan Bohrer CPA	Vice President of Finance & Accounting
Mr. Christopher Thurston	Chief Technology Officer
Mr. Andrew Benson	Head of Investor Relations
Dr. Mayuranki Almaula Ph.D.	Senior Vice President of Overseas Operations & Strategic Alliances
Mr. Seth Egan	Chief Commercialization Officer

Important FAQs about investing in CODX Stock from India :

What is Co-diagnostics share price today?

Co-diagnostics share price today is $0.33 as on August 30, 2025 at 1:29 am IST at the close of the market. Co-diagnostics share today touched a day high of $0.34 and a low of $0.33.

What is the 52 week high and 52 week low for Co-diagnostics share?

Co-diagnostics share touched a 52 week high of $1.58 and a 52 week low of $0.23. Co-diagnostics stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $0.33, lower by 79.11% versus the 52 week high.

How to invest in Co-diagnostics Stock (CODX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Co-diagnostics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Co-diagnostics Shares that will get you 4.5455 shares as per Co-diagnostics share price of $0.33 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Co-diagnostics Stock (CODX) from India?

Indian investors can start investing in Co-diagnostics (CODX) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Co-diagnostics stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Co-diagnostics share’s latest price of $0.33 as on August 30, 2025 at 1:29 am IST, you will get 30.3030 shares of Co-diagnostics. Learn more about fractional shares .

What are the returns that Co-diagnostics has given to Indian investors in the last 5 years?

Co-diagnostics stock has given -96.88% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?